MetLife Investment Management’s Emergent Biosolutions EBS Stock Holding History

MetLife Investment Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$251K	Buy	29,933 +4,696	+19%	+$39.3K	﹤0.01%	2303
2026 Q1	$209K	Sell	25,237 -6,182	-20%	-$64K	﹤0.01%	2203
2025 Q4	$388K	Buy	31,419 +4,986	+19%	+$53.4K	﹤0.01%	1915
2025 Q3	$233K	Sell	26,433 -6,249	-19%	-$48.6K	﹤0.01%	2230
2025 Q2	$209K	Buy	+32,682	New	+$187K	﹤0.01%	2165
2024 Q1	–	Sell	-27,395	Closed	-$65.7K	–	2794
2023 Q4	$65.7K	Hold	27,395	–	–	﹤0.01%	2749
2023 Q3	$93.1K	Hold	27,395	–	–	﹤0.01%	2616
2023 Q2	$201K	Hold	27,395	–	–	﹤0.01%	2274
2023 Q1	$284K	Hold	27,395	–	–	﹤0.01%	2001
2022 Q4	$324K	Hold	27,395	–	–	﹤0.01%	1919
2022 Q3	$575K	Hold	27,395	–	–	﹤0.01%	1535
2022 Q2	$850K	Hold	27,395	–	–	0.01%	1295
2022 Q1	$1.12M	Buy	27,395 +9,797	+56%	+$432K	0.01%	1258
2021 Q4	$765K	Sell	17,598 -22,960	-57%	-$1.04M	0.01%	1254
2021 Q3	$2.03M	Buy	40,558 +201	+0.5%	+$12.2K	0.02%	851
2021 Q2	$2.54M	Sell	40,357 -643	-2%	-$41.3K	0.02%	766
2021 Q1	$3.81M	Sell	41,000 -2,365	-5%	-$242K	0.03%	535
2020 Q4	$3.89M	Sell	43,365 -1,105	-2%	-$101K	0.04%	480
2020 Q3	$4.6M	Buy	44,470 +24,459	+122%	+$2.64M	0.05%	341
2020 Q2	$1.58M	Hold	20,011	–	–	0.02%	827
2020 Q1	$1.16M	Hold	20,011	–	–	0.02%	838
2019 Q4	$1.08M	Hold	20,011	–	–	0.01%	1063
2019 Q3	$1.05M	Hold	20,011	–	–	0.01%	1044
2019 Q2	$967K	Sell	20,011 -40,022	-67%	-$1.92M	0.01%	1118
2019 Q1	$3.03M	Buy	60,033 +40,022	+200%	+$2.36M	0.01%	1056
2018 Q4	$1.19M	Buy	20,011 +1,170	+6%	+$75.4K	0.01%	957
2018 Q3	$1.24M	Sell	18,841 -1,671	-8%	-$97.5K	0.01%	1035
2018 Q2	$1.04M	Buy	20,512 +4,795	+31%	+$250K	0.01%	1005
2018 Q1	$828K	Hold	15,717	–	–	0.01%	1093
2017 Q4	$730K	Buy	+15,717	New	+$662K	0.01%	1182

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

MetLife Investment Management's EBS Position: Q2 2026 in Review

MetLife Investment Management increased its Emergent Biosolutions (EBS) stake by 19% in Q2 2026, buying an estimated $39.3K and bringing the position to 29,933 shares worth $251K. The position accounts for ﹤0.01% of the portfolio, ranked #2303.

MetLife Investment Management first reported a position in EBS in Q4 2017 and has held it in 30 quarters since. The position peaked at $4.6M in Q3 2020. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

MetLife Investment Management held 29,933 shares of Emergent Biosolutions worth $251K as of Q2 2026.
MetLife Investment Management bought 4,696 Emergent Biosolutions shares in Q2 2026, an estimated $39.3K.
Emergent Biosolutions made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2303 holding.
MetLife Investment Management first reported a position in Emergent Biosolutions in Q4 2017 and has held it in 30 quarters since.
MetLife Investment Management's Emergent Biosolutions position peaked at $4.6M in Q3 2020.
194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.